+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sotagliflozin Market - Global Forecast 2026-2032- Product Image
Sotagliflozin Market - Global Forecast 2026-2032- Product Image
Sale

Sotagliflozin Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6153475
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sotagliflozin Market is projected to reach USD 832.49 Million in 2026. It is expected to continue growing at a CAGR of 4.65%, reaching USD 1.09 Billion by 2032.

Sotagliflozin: Executive Summary and Market Context

Sotagliflozin is an orally administered dual sodium-glucose cotransporter 1 and 2 inhibitor. Its clinical profile has been studied across cardiometabolic conditions, including heart failure, type 2 diabetes, and chronic kidney disease. The product’s relevance is shaped by evidence on cardiovascular outcomes, renal protection, glycemic control, safety, regulatory decisions, reimbursement, and appropriate patient selection. Interpretation should distinguish approved indications and labeling from investigational uses in each jurisdiction.

Clinical Evidence and Treatment-Pathway Shifts

Sotagliflozin reflects a broader shift toward therapies that address interconnected cardiovascular, renal, and metabolic risks rather than glucose control alone. Its dual mechanism combines reduced renal glucose and sodium reabsorption through SGLT2 inhibition with intestinal SGLT1 inhibition, which may affect postprandial glucose handling. Clinical adoption depends on the strength and consistency of outcome evidence, comparisons with established treatment pathways, adverse-event management, and integration with guideline-directed care. Key considerations include volume depletion, genital or urinary infections, ketoacidosis risk, renal function, and perioperative treatment interruption.

Artificial Intelligence in Sotagliflozin Development and Care

Artificial intelligence can support sotagliflozin research by improving trial recruitment, identifying clinically relevant subgroups, detecting safety signals, and integrating laboratory, claims, imaging, and electronic health-record data. In clinical practice, predictive tools may help identify patients at elevated risk of heart failure events or kidney-function decline, while decision support can reinforce contraindication screening and monitoring. These applications require representative datasets, transparent validation, privacy safeguards, and clinician oversight. AI should complement, not replace, evidence from randomized trials and regulatory review.

Regional Insights Across Six Health-System Environments

North America is characterized by extensive cardiovascular and diabetes research capacity, sophisticated payer evaluation, and close attention to label-specific outcomes and real-world evidence. Europe combines centralized scientific guidance with country-level reimbursement decisions and emphasis on health technology assessment. Asia-Pacific presents substantial variation in disease burden, regulatory pathways, affordability, and access to specialist care. Latin America’s use is influenced by public-sector procurement, private coverage, and uneven diagnostic capacity. Middle Eastern systems vary widely in funding, specialist infrastructure, and chronic-disease priorities, while Africa faces greater constraints in diagnosis, medicine access, renal monitoring, and pharmacovigilance. Across all regions, sustainable adoption depends on appropriate patient identification and follow-up capacity.

Group Insights for ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets differ in regulatory maturity, reimbursement design, and access to cardiometabolic specialists, making adaptable evidence-generation and education strategies important. BRICS members span highly diverse public and private systems, with local manufacturing, procurement, and affordability considerations affecting availability. The European Union benefits from shared scientific and regulatory structures but retains national variation in reimbursement and clinical implementation. G7 systems generally have strong evidence infrastructure and demanding value assessments. GCC countries often combine high specialist capacity with centralized purchasing and significant cardiometabolic disease burdens. NATO members are not a uniform health-policy bloc, but many share advanced safety surveillance and clinical research capabilities; country-specific rules remain decisive.

Country-Level Considerations for Access and Clinical Use

Australia emphasizes regulatory assessment, specialist prescribing, and public reimbursement criteria. Brazil combines a large public system with private coverage and regional variation in access. Canada’s provincial decision-making is important after federal authorization. China’s adoption depends on national regulatory review, reimbursement processes, and hospital formulary integration. France, Germany, Italy, and Spain operate within the European framework while applying distinct assessment, pricing, and prescribing practices. India’s diverse public-private system makes affordability, diagnostic access, and physician education central. Japan and South Korea place strong weight on local evidence, regulatory requirements, and structured clinical practice. Mexico faces differences between public and private access. Russia’s use is shaped by national authorization, procurement, and healthcare-system conditions. The United Kingdom relies on national guidance and separate implementation across its constituent systems. The United States is influenced by federal authorization, payer coverage, specialist adoption, and safety monitoring.

Action Priorities for Sotagliflozin Industry Leaders

Industry leaders should prioritize label-aligned evidence that clarifies which patients derive meaningful cardiovascular, renal, and metabolic benefit. Evidence plans should include diverse populations, long-term safety monitoring, treatment persistence, and outcomes relevant to payers and clinicians. Implementation efforts should provide practical protocols for renal assessment, volume status, infection prevention, ketoacidosis risk reduction, and perioperative interruption. Regional strategies should reflect local regulatory and reimbursement requirements rather than assume uniform uptake. Responsible use of AI requires auditable models, bias testing, cybersecurity, and clear accountability. Partnerships with healthcare systems can improve diagnosis, adherence support, and pharmacovigilance without overstating unapproved benefits.

Research Methodology for the Sotagliflozin Executive Summary

This summary uses a structured review of the supplied market topic and established public-domain evidence categories relevant to sotagliflozin, including regulatory information, clinical-trial findings, peer-reviewed research, treatment guidelines, health technology assessment principles, and healthcare-system context. Findings are synthesized qualitatively across the specified regions, groups, and countries. No market estimates, market shares, forecasts, or company-specific claims are included. Regulatory status, approved indications, and reimbursement conditions should be verified against current jurisdiction-specific sources because they can change over time.

Conclusion: Evidence-Led Positioning of Sotagliflozin

Sotagliflozin occupies an important position in the development of integrated cardiometabolic treatment because its dual SGLT1 and SGLT2 mechanism is relevant to both glucose handling and cardiorenal risk. Its practical role will depend on indication-specific evidence, safety management, patient selection, affordability, and health-system readiness. Leaders should pair rigorous outcomes research with regionally tailored implementation, transparent AI governance, and continuous post-authorization monitoring. A disciplined, label-consistent approach is essential to translate clinical evidence into responsible patient benefit.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Sotagliflozin Market, by Indication
7.1. Introduction
7.2. Type 1
7.2.1. Adult
7.2.2. Pediatric
7.3. Type 2
7.3.1. Adult
7.3.2. Pediatric
8. Sotagliflozin Market, by Dosage Strength
8.1. Introduction
8.2. 200 Mg
8.3. 400 Mg
9. Sotagliflozin Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Private
9.2.2. Public
9.3. Online Pharmacies
9.3.1. Direct-to-Consumer
9.3.2. Third-Party Platforms
9.4. Retail Pharmacies
9.4.1. Chain
9.4.2. Independent
10. Sotagliflozin Market, by Region
10.1. Introduction
10.2. Asia-Pacific
10.3. North America
10.4. Latin America
10.5. Europe
10.6. Middle East
10.7. Africa
11. Sotagliflozin Market, by Group
11.1. Introduction
11.2. ASEAN
11.3. GCC
11.4. European Union
11.5. BRICS
11.6. G7
11.7. NATO
12. Sotagliflozin Market, by Country
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. United Kingdom
12.7. Germany
12.8. France
12.9. Russia
12.10. Italy
12.11. Spain
12.12. China
12.13. India
12.14. Japan
12.15. Australia
12.16. South Korea
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. Market Concentration Analysis, 2025
13.2.1. Concentration Ratio (CR)
13.2.2. Herfindahl Hirschman Index (HHI)
13.3. Recent Developments & Impact Analysis, 2025
13.4. Product Portfolio Analysis, 2025
13.5. Benchmarking Analysis, 2025
14. Company Profiles
14.1. ALP Pharm
14.2. Clearsynth
14.3. Conscientia Industrial Co. Ltd.
14.4. F.I.S. Fabbrica Italiana Sintetici
14.5. HRV Pharma
14.6. Lexicon Pharmaceuticals, Inc.
14.7. MedKoo Biosciences
14.8. Metrochem API Private Limited
14.9. Metrochem API Private Limited
14.10. Moehs Iberica
14.11. Sanofi S.A.
14.12. Saptagir Laboratories
14.13. Simson Pharma Limited
14.14. Taiclone Biotech
14.15. TAPI Technology & API Services
14.16. TargetMol
14.17. Viatris Inc.
15. Key Experts
LIST OF FIGURES
FIGURE 1. Global Sotagliflozin Market, Years Considered for the Study
FIGURE 2. Global Sotagliflozin Market, Research Design
FIGURE 3. Global Sotagliflozin Market, Research Framework
FIGURE 4. Global Sotagliflozin Market, Data Triangulation
FIGURE 5. Global Sotagliflozin Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Sotagliflozin Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Sotagliflozin Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Sotagliflozin Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 9. Global Sotagliflozin Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Sotagliflozin Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Sotagliflozin Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Sotagliflozin Market Size, by Region, 2025 vs 2032 (%)
FIGURE 13. Global Sotagliflozin Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Sotagliflozin Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 15. Global Sotagliflozin Market Size, by Country, 2025 vs 2032 (%)
FIGURE 16. Global Sotagliflozin Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Sotagliflozin Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Sotagliflozin Market Segmentation & Coverage
TABLE 2. Global Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 3. Global Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Type 1 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Type 1 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Type 1 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Type 2 Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Type 2 Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Type 2 Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 23. Global 200 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global 200 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global 200 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global 400 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global 400 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global 400 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 30. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Private Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Private Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Private Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Public Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Public Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Public Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Direct-to-Consumer Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Direct-to-Consumer Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Direct-to-Consumer Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Third-Party Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Third-Party Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Third-Party Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Chain Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Chain Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Chain Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Independent Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Independent Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Independent Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 67. North America Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. North America Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 69. North America Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 70. North America Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 71. North America Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 72. North America Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. North America Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 74. North America Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 75. North America Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 76. Latin America Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Latin America Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Latin America Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 79. Latin America Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 80. Latin America Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 81. Latin America Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Latin America Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 83. Latin America Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 84. Latin America Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 85. Europe Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Europe Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. Europe Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 88. Europe Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 89. Europe Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 90. Europe Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Europe Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 92. Europe Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 93. Europe Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 94. Middle East Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Middle East Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 96. Middle East Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 97. Middle East Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 98. Middle East Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 99. Middle East Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 100. Middle East Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 101. Middle East Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 102. Middle East Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 103. Africa Sotagliflozin Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Africa Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 105. Africa Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 106. Africa Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 107. Africa Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 108. Africa Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Africa Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 110. Africa Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 111. Africa Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 112. Global Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. ASEAN Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. ASEAN Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. ASEAN Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 116. ASEAN Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 117. ASEAN Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 118. ASEAN Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. ASEAN Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 120. ASEAN Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 121. ASEAN Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 122. GCC Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. GCC Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. GCC Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 125. GCC Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 126. GCC Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 127. GCC Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. GCC Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 129. GCC Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 130. GCC Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 131. European Union Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. European Union Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 133. European Union Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 134. European Union Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 135. European Union Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 136. European Union Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. European Union Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 138. European Union Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 139. European Union Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 140. BRICS Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. BRICS Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. BRICS Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 143. BRICS Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 144. BRICS Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 145. BRICS Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. BRICS Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 147. BRICS Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 148. BRICS Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 149. G7 Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. G7 Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. G7 Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 152. G7 Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 153. G7 Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 154. G7 Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. G7 Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 156. G7 Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 157. G7 Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 158. NATO Sotagliflozin Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. NATO Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. NATO Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 161. NATO Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 162. NATO Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 163. NATO Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. NATO Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 165. NATO Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 166. NATO Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 167. Global Sotagliflozin Market Size, by Country, 2017-2032 (USD Million)
TABLE 168. United States Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 169. United States Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. United States Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 171. United States Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 172. United States Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 173. United States Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. United States Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 175. United States Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 176. United States Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 177. Canada Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 178. Canada Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Canada Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 180. Canada Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 181. Canada Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 182. Canada Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Canada Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 184. Canada Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 185. Canada Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 186. Mexico Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 187. Mexico Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. Mexico Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 189. Mexico Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 190. Mexico Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 191. Mexico Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. Mexico Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 193. Mexico Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 194. Mexico Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 195. Brazil Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 196. Brazil Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. Brazil Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 198. Brazil Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 199. Brazil Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 200. Brazil Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. Brazil Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 202. Brazil Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 203. Brazil Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 204. United Kingdom Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 205. United Kingdom Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. United Kingdom Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 207. United Kingdom Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 208. United Kingdom Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 209. United Kingdom Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. United Kingdom Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 211. United Kingdom Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 212. United Kingdom Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 213. Germany Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 214. Germany Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. Germany Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 216. Germany Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 217. Germany Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 218. Germany Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. Germany Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 220. Germany Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 221. Germany Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 222. France Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 223. France Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. France Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 225. France Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 226. France Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 227. France Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. France Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 229. France Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 230. France Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 231. Russia Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 232. Russia Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Russia Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 234. Russia Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 235. Russia Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 236. Russia Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Russia Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 238. Russia Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 239. Russia Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 240. Italy Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 241. Italy Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. Italy Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 243. Italy Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 244. Italy Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 245. Italy Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Italy Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 247. Italy Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 248. Italy Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 249. Spain Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 250. Spain Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. Spain Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 252. Spain Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 253. Spain Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 254. Spain Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Spain Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 256. Spain Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 257. Spain Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 258. China Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 259. China Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. China Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 261. China Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 262. China Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 263. China Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 264. China Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 265. China Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 266. China Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 267. India Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 268. India Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 269. India Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 270. India Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 271. India Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 272. India Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 273. India Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 274. India Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 275. India Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 276. Japan Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 277. Japan Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 278. Japan Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 279. Japan Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 280. Japan Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 281. Japan Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. Japan Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 283. Japan Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 284. Japan Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 285. Australia Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 286. Australia Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 287. Australia Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 288. Australia Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 289. Australia Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 290. Australia Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 291. Australia Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 292. Australia Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 293. Australia Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 294. South Korea Sotagliflozin Market Size, 2017-2032 (USD Million)
TABLE 295. South Korea Sotagliflozin Market Size, by Indication, 2017-2032 (USD Million)
TABLE 296. South Korea Sotagliflozin Market Size, by Type 1, 2017-2032 (USD Million)
TABLE 297. South Korea Sotagliflozin Market Size, by Type 2, 2017-2032 (USD Million)
TABLE 298. South Korea Sotagliflozin Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 299. South Korea Sotagliflozin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 300. South Korea Sotagliflozin Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 301. South Korea Sotagliflozin Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 302. South Korea Sotagliflozin Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 303. Global Sotagliflozin Market Share, by Key Player, 2025
TABLE 304. Global Sotagliflozin Market, Key Experts

Companies Mentioned

  • ALP Pharm
  • Clearsynth
  • Conscientia Industrial Co. Ltd.
  • F.I.S. Fabbrica Italiana Sintetici
  • HRV Pharma
  • Lexicon Pharmaceuticals, Inc.
  • MedKoo Biosciences
  • Metrochem API Private Limited
  • Metrochem API Private Limited
  • Moehs Iberica
  • Sanofi S.A.
  • Saptagir Laboratories
  • Simson Pharma Limited
  • Taiclone Biotech
  • TAPI Technology & API Services
  • TargetMol
  • Viatris Inc.

Related Topics

Related Reports

SGLT2 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

SGLT2 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 100 Pages
  • Global
From
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2026 - Product Image

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Linagliptin & Metformin Hydrochloride Tablets Market - Global Forecast 2026-2032 - Product Image

Linagliptin & Metformin Hydrochloride Tablets Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Glucagon Like Peptide-1 Agonists Market - Global Forecast 2026-2032 - Product Image

Glucagon Like Peptide-1 Agonists Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Diabetes Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Diabetes Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Drug Pipelines
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.